Review

Bisphosphonate-related atypical femoral fracture: Managing a rare but serious complication

Stuart Silverman, MD, Eli Kupperman, MD and Susan Bukata, MD
Cleveland Clinic Journal of Medicine November 2018, 85 (11) 885-893; DOI: https://doi.org/10.3949/ccjm.85a.17119

ABSTRACT

Atypical femoral fracture is a rare but serious complication of long-term bisphosphonate therapy. Although the benefit of preventing osteoporotic fractures greatly outweighs the risk of atypical fracture in bisphosphonate users, concern about atypical fracture risk has led to a decrease in bisphosphonate use. What are the risks, and how do we treat atypical femoral fracture?

Footnotes

  • Dr. Silverman has disclosed commercial interests (consulting, board membership, teaching, and speaking) with Amgen, Eli Lilly, Pfizer, Radius Health, and Roche Pharmaceuticals.

  • Dr. Bukata has disclosed commercial interests (consulting, teaching, and speaking) with Amgen, Eli Lilly, and Radius Health.

View Full Text
  1. Stuart Silverman, MD⇑
  1. Cedars-Sinai Medical Center, Los Angeles, CA; Medical Director, OMC Clinical Research Center, Beverly Hills, CA; Clinical Professor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
  1. ADDRESS:
    Stuart Silverman, MD, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211; stuarts{at}bhillsra.com
  1. Eli Kupperman, MD
  1. Department of Orthopaedic Surgery, University of California, Los Angeles
  1. Susan Bukata, MD
  1. David Geffen School of Medicine at UCLA, Los Angeles, CA

ABSTRACT

Atypical femoral fracture is a rare but serious complication of long-term bisphosphonate therapy. Although the benefit of preventing osteoporotic fractures greatly outweighs the risk of atypical fracture in bisphosphonate users, concern about atypical fracture risk has led to a decrease in bisphosphonate use. What are the risks, and how do we treat atypical femoral fracture?

Footnotes

  • Dr. Silverman has disclosed commercial interests (consulting, board membership, teaching, and speaking) with Amgen, Eli Lilly, Pfizer, Radius Health, and Roche Pharmaceuticals.

  • Dr. Bukata has disclosed commercial interests (consulting, teaching, and speaking) with Amgen, Eli Lilly, and Radius Health.

View Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects